期刊文献+

米氮平与舍曲林治疗抑郁症的对照研究 被引量:6

Control study of mirtazapine versus sertraline in the treatment of depression
下载PDF
导出
摘要 目的比较米氮平与舍曲林治疗抑郁症的临床疗效与安全性。方法对分别接受米氮平和舍曲林的66例抑郁症患者进行为期6周的观察,并应用17项汉密尔顿抑郁量表(HAMD-17)和TESS量表评估和比较这两种药物治疗抑郁症的疗效和安全性。结果治疗1周后,米氮平组的HAMD评分低于舍曲林组,差异有显著性(P<0.05)。治疗6周后,米氮平组有效率和治愈率分别为91.6%和62.5%,与舍曲林组(88.2%和61.8%)比较无显著性差异(P>0.05)。与舍曲林组相比,米氮平组每次TESS评分均低于舍曲林组,差异有显著性(P<0.05)。结论米氮平是一种安全、有效的新型抗抑郁药物,起效较快。 Objective To evaluate the therapeutic effect and safety of mirtazapine and sertraline in treatment of depression. Methods 66 patients with diagnosis of depressive disorder according to ICD - 10 criteria were randomized into mirtazapine group and sertraline group, which were treated with mirtazapine (15 -45mg/d) and sertraline (20 - 40mg/d) respectively for 6 weeks. Atidepressive effect and side effect were evaluated with 17 - item Hamilton depression rating scale for depresssion ( HAMD - 17 ) and treatment emergent symptom scale (TESS). Results At the end of 1 st week, the score of HAMD in mirtazapine group was significantly lower than in sertraline group ( P 〈 0.05 ). At the end of 6th week, there were no significant differences in effective rate ( 91.6% vs 88.2% ) or recovery rate (62.5% vs 61. 8% ) between mirtazapine group and sertraline group (P 〉 0. 05). The scores of TESS at every viewpoints in mirtazapine group were significantly lower than those in sertraline group ( P 〈 0.05 ). Conclusion Mirtazapine is a safe, effective antidepressant with rapid response.
作者 田甜 郭新宇
机构地区 天津市安定医院
出处 《精神医学杂志》 2011年第1期34-36,共3页 Journal of Psychiatry
关键词 米氮平 舍曲林 抑郁症 Mirtazapine Sertraline Depression
  • 相关文献

参考文献10

  • 1Massat I,Souery D,Lipp O,et al.A european multticenter association study of HTR2A receptor polymorphism in bipolar affective disorder[J].Am J Med Genet,2000,96(2):136. 被引量:1
  • 2Tut TG,Wang JL,Lim CC.Negative association between T102C polymorphism at the 5-HT2A receptor gene and bipolar affective disorders in Singaporean Chinese[J].J Affect Disord,2000,58(3):211. 被引量:1
  • 3谢光荣,陈风华,赵敏,张向晖,苏林雁.5HT_(2A)受体基因T102C多态性与情感性精神障碍的关联研究[J].中国神经精神疾病杂志,2002,28(1):50-51. 被引量:14
  • 4Arias B,Gasto C,Catalan R,et al.The 5-HT2A receptor gene 102T/C polymorphism is associated with suicidal behavior in depressed patients[J].Am J Med Genet,2001,105(8):801. 被引量:1
  • 5Fehr C,Szegedi A,Anghelescu I,et al.Sex differences in allelic frequencies of the 5-HT2C Cys23Ser polymorphism in psychiatric patients and healthy volunteers:findings from an association study[J].Psychiatr Genet,2000,10(2):59. 被引量:1
  • 6陈晓岗,谭立文,赵靖平,李乐华,陈远光.瑞美隆与氟西汀治疗抑郁症的临床及心理学评价[J].中国临床心理学杂志,2002,10(2):100-102. 被引量:18
  • 7Wheatly DP,V anMoff:aertm,T immermanl,et al.M irtazap ine:efficacy and to lerability in comparison w ith fluoxetine inpatients with moderate to sever major depressive[J].J Gin Psychiatry,1998,59:306. 被引量:1
  • 8陈涛,陈昌利,江永,郑华胜.米氮平与帕罗西汀治疗抑郁症疗效对照[J].中国现代医生,2009,47(34):38-39. 被引量:12
  • 9Tarsitani L,Pasquini M.Compared with fluoxetine monotherapy,mirtazapine plus venlafaxine or fluoxetine increase remission but not response in patients with major depressive disorder[J].Evid Based Ment Health,2010,13(3):83. 被引量:1
  • 10Fang Y,Yuan C,Xu Y,et al.Comparisons of the efficacy and tolerability of extended-release venlafaxine,mirtazapine,and paroxetine in treatment-resistant depression:a doubleblind,randomized pilot study in a Chinese population[J].J Clin Psychopharmacol,2010,30(4):357 -364. 被引量:1

二级参考文献17

  • 1郭慧荣,任玉明,李淑英.米氮平与米安色林治疗老年抑郁症的对照研究[J].中国心理卫生杂志,2005,19(7):489-491. 被引量:17
  • 2Anttila SA,leinonen EA. A review of the pharmacological and clinical profile of Mirtazapine[J]. C NS Drug Rev, 2001,21 (7) : 249-264. 被引量:1
  • 3中华医学院会精神科分会编.中国精神疾病分类与诊断标准[M].第3版.济南:山东科学技术出版社,2001:87-88. 被引量:1
  • 4Benker O,Szegedi A,Kohnen R. Mirtazapine compared with paroxetine in major depression[J]. J Clin Psyehiat, 2000,61 (9) : 656-663. 被引量:1
  • 5沈渔邨.精神病学[J].第4版.北京:人民卫生出版社,2003:692-696. 被引量:1
  • 6[1]Jablensky A: Prediction of the course and outcome of depression. Psyc hological Medicine, 1987; 17: 1-9 被引量:1
  • 7[2]Cookson J: Side-effects of antidepressants. Br J Psychiatry, 1993; 163(suppl. 20): 20-40 被引量:1
  • 8[3]Cowen P, Power AC: Combination treatment of depression. Br J Psychiatry, 1993 ;162: 266-267 被引量:1
  • 9[4]Arya D: Extrapyramidal symptoms with SSRIs. Br J Psychiatry, 1994; 165: 728- 733 被引量:1
  • 10[5]Boer TD, Ruigt GSF, Berendsen HHG, et al: The α2- adrenoceptor antagonist mirtazapine enhances noradrenergic and serotonergic transmission. Hum Psychopharmacol. 1995; 10: S107-108 被引量:1

共引文献40

同被引文献47

引证文献6

二级引证文献33

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部